A Randomized, Open-label, Single-Dose, Parallel Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1803 in Healthy Male Volunteers
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Amosartan plus L (Primary) ; HCP1904-1
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 20 Sep 2023 Status has been changed to completed.
- 14 Feb 2023 New trial record